Диссертация (1139537), страница 48
Текст из файла (страница 48)
Chapman // Pharmacol. Rev. – 2006. – Vol. 58, N 3. – P. 342–374.295. Kormeili T. Psoriasis: immunopathogenesis and evolving immunomodulators andsystemic therapies ; U.S. experiences. Topical Review / T. Kormeili, N.J. Lowe,P.S. Yamauchi // Brit. J. of Dermatology. – 2004. – Vol. 151. – P. 3–15.296. Krueger J.G. The immunologic basis for the treatment of psoriasis with newbiologic agents / J.G.
Krueger // J. Am. Acad. Dermatol. – 2002. – Vol. 46. – P. 1–23.297. Lampl Y. Laser treatment for stroke / Y. Lampl // Expert Rev. Neurother. – 2007.– № 7. – P. 961–965.298. Lee L. Metabolic manipulation in ischaemic heart disease, a novel approach totreatment / L. Lee, J. Horowitz, M. Frenneaux // Eur.
Heart J. – 2004. – Vol. 25. –P. 634–641.299. Leonardi C. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a /C. Leonardi // Semin. Cutan. Med. Surg. – 2016. – Vol. 35, № 4, Suppl. 4. – P.S74–77.300. Liakou A.I. Links and risks associated with psoriasis and metabolic syndrome /A.I. Liakou, C.C. Zouboulis // Psoriasis (Auckl). – 2015. – Vol. 2, № 5. – P. 125–128.301. Longterm (52-week) results of a phase III randomized, controlled trial ofapremilast in patients with psoriatic arthritis / A. Kavanaugh [et al.] // J. Rheumatol.– 2015. – Vol.
42, № 3. – P. 479–488.302. Low level laser therapy in inflammatory and infectious oral diseases / C.V. André[et al.] // Rev. Stomatol. Chir. Maxillofac. Chir. Orale. – 2014. – Vol. 115, № 1. –P. 22–27.303. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring / P.Avci [et al.] // Semin.
Cutan. Med. Surg. – 2013. – Vol. 32, № 1. – P. 41–52.304. Low-level laser therapy for wound healing: mechanism and efficacy / W. Posten[et al.] // Dermatol. Surg. – 2005. – Vol. 31, № 3. – P. 334–340.269305. Machado-Pinto J. Psoriasis: new comorbidities / J. Machado-Pinto, M. SantosDiniz, N. Couto Bavoso // An. Bras. Dermatol. – 2016. – Vol. 91, № 1. – P. 8–14.306. Mahil S.K. Psoriasis: from gene to clinic congress report / S.K. Mahil //Supplement to the Journal of clinical and aesthetic dermatology.
– 2015. – Vol. 8,№ 7. – P. 17–22.307. Mantzoros C.S. The role of leptin and hypothalamic neuropeptides in energyhomeostasis: update on leptin in obesity / C.S. Mantzoros // Growth Horm. IGFRes. – 2001. – № 11, Suppl. A. – P. 85–89.308. Metabolic syndrome in Portugal: prevalence and implications for cardiovascularrisk – result from the VALSIM Study / M.
Fiuza [et al.] // Rev. Port. Cardiol. –2008. – Vol. 27, № 12. – P. 1495–1529.309. Metabolic syndrome prevalence in Russia: Prelimonary results of a cross –sectional population study / M. Mamedov [et al.] // Diab. Vase Dis. res. – 2007. –Vol. 4, № 1.
– P. 46–47.310. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? / S. Karaca[et al.] // Sleep Breath. – 2013. – Vol. 17. – P. 275–280.311. Moon H.S. Psoriasis and psycho-dermatology / H.S. Moon, A. Mizara, S.R.McBride // Dermatol. Ther. (Heidelb).
– 2013. – Vol. 3, № 2. – P. 117-130.312. Murphy J.E. Interleukin-1 and cutaneous inflammation: a crucial link betweeninnate and acquired immunity / J.E. Murphy, C. Robert, T.S. Kupper // J. Invest.Dermatol. – 2000. – Vol. 114. – P. 602–608.313. Naldi L. Dietary factors and the risk of psoriasis. Results of an Italian case–controlstudy / L. Naldi // Br. J.
Dermatol. – 1996. – Vol. 134. – P. 101–106.314. Narrative review: the role of leptin in human physiology: emerging clinicalapplications / T. Kelesidis [et al.] // Ann. Intern. Med. – 2010. – Vol. 19, № 2. – P.93–100.315. Neuroprotective and antiamnesic effects of Semax during experimental ischemicinfarction of the cerebral cortex / G.A. Romanova [et al.] // Bull. Exp. Biol. Med.– 2007. – Vol. 142, № 6. – P. 663–666.270316. Nevitt G.J. Psoriasis in the community: prevalence, severity and patients beliefsand altitudes towards the disease / G.J. Nevitt, P.E.
Hutchinson // Br. J. Dermatol.– 1996. – Vol. 135, № 4. – P. 533–537.317. Ni C. Psoriasis and comorbidities: links and risks / C. Ni, M.W. Chiu // Clin.Cosmet. Investig. Dermatol. – 2014. – Vol. 17. – P. 119–132.318. Nickoloff B.J. Immunopathogenesis of psoriasis: lessons learned from theSCID mouse: human skin animal model / B.J. Nickoloff // Dermatology at themiller. – 2000.
– P. 483–486.319. Nicoloff B.J. Characterization of lymphocytedependent angiogenesis using ascidmous: а human skin model of psoriasis / B.J. Nicoloff // J. invest. Dermatol. Symp.Proa. – 2000. – Vol. 5, № L. – P. 67–73.320. Obesity, waist circumference, weight change and the risk of psoriasis in US women/ S. Kumar [et al.] // J. Eur. Acad Dermatol Venereol. – 2013. – Vol.
27, № 10. –P. 1293–1298.321. Olson G.A. Endogenous opiates / G.A. Olson, R.D. Olson, A.J. Kastin // Peptides.– 1985. – Vol. 6, № 4. – P. 769–791.322. O'Rielly D.D. Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis andPsoriatic Arthritis / D.D. O'Rielly, P. Rahman // Rheum.
Dis. Clin. North Am. –2015. – Vol. 41, № 4. – P. 623–642.323. Oxidative stress and psoriasis: the effect of antitumour necrosis-α-inhibitortreatment / T. Bacchetti [et al.] // Br. J. Dermatol. – 2013. – Vol. 168, № 5. – P.984–989.324. Panconesi E. Stress, stigmatisation and psychosomatic purpuras / E. Panconesi, G.Hautmann // Int. Angiol. – 1995. – Vol. 14, № 2. – P. 130–137.325. Parisi R.
Global epidemiology of psoriasis: a systematic review of incidence andprevalence / R. Parisi, C.E. Griffiths, D.M. Acroft // J. Invest. Dermatol. – 2013. –Vol. 133. – P. 377–385.326. Patients with psoriasis feel stigmatized / E. Hrehorów [et al.] // Acta Derm.Venereol.
– 2012. – Vol. 92, № 1. – P. 67–72.327. Physical and psychologic measures are necessary to assess overall psoriasis271severity / B. Kirby [et al.] // J. Am. Acad. Dermatol. – 2001. – Vol. 45, № 1. – P.72–76.328. Presence of selected metabolic syndrome components in patients with psoriasisvulgaris / S. Uczniak [et al.] // Postepy Dermatol. Alergol. – 2016.
– Vol. 33, № 2.– P. 114–119.329. Prevalence of metabolic syndrome and cardiovascular changes in patients withchronic plaque psoriasis and their correlation with disease severity: A hospitalbased cross-sectional study / S.K. Kothiwala [et al.] // Indian J. Dermatol.Venereol. Leprol. – 2016. – Vol. 82, № 5. – P. 510–518.330. Prinz J.C. Psoriasis vulgaris – a sterile antibacterial skin reaction mediated bycross–reactive T cells.
An immunological view of the pathophysiology of psoriasis/ J.C. Prinz // Clinical and Experimental Dermatology. – 2001. – Vol. 26, № 4. –P. 326–332.331. Prinz J.C. The role of streptococci in psoriasis / J.C. Prinz // Hautarzt. – 2009. –Vol. 60, № 2. – P. 109–115.332. Psoriasis alters HDL composition and cholesterol efflux capacity / M.
Holzer [etal.] // J. Lipid Res. – 2012. – Vol. 53, № 8. – P. 1618–1624.333. Psoriasis and depression / A. Chamoun [et al.] // Rev. Med. Brux. – 2015. – Vol.36, № 1. – P. 23–28.334. Psoriasis and dyslipidaemia: a populationbased study / J. Dreiher [et al.] // ActaDerm. Venereol. – 2008. – Vol. 88. – P. 561–565.335. Psoriasis and streptococci: the natural selection of psoriasis revisited / J.P.McFadden [et al.] // Br.
J. Dermatol. – 2009. – Vol. 160. – P. 929–937.336. Psoriasis and the nervous system / C. Pincelli [et al.] // Acta Derm. Venereol. Suppl.(Stockh). – 1994. – Vol. 186. – P. 60–61.337. Psoriasis decreases the anti-oxidation and anti-inflammation properties of highdensity lipoprotein / L. He [et al.] // Biochim.
Biophys. Acta. – 2014. – Vol. 1841,№ 12. – P. 1709-1715.272338. Psychological approach to different skin diseases: life events and tendency tocomplain / D. Tordeurs [et al.] // Ann. Dermatol. Venereol. – 2001. – Vol. 128, №1. – P. 21–24.339. Quality of life and work productivity impairment among psoriasis patients:findings from the National Psoriasis Foundation survey data 2003-2011 / A.W.Armstrong [et al.] // PLoS One. – 2012. – № 7. – e52935.340. Qxydant/antioxidant status in patients with psoriasis / K.
Baz [et al.] // Yonsei Med.J. – 2003. – Vol. 44, № 6. – P. 987–990.341. Rajiv J. Immunopathogenesis of psoriasis / J. Rajiv // Indian J. of Dermatology,Venereology and Leprology. – 2004. – Vol. 70, № 1. – P. 10–12.342. Ramley A.G. Analitic aspects of antioxidants and free radicals activity in clinicalbiochemistry / A.G. Ramley, J.R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
